NewAmsterdam Pharma (NAMS) Net Margin (2023 - 2025)
NewAmsterdam Pharma's Net Margin history spans 3 years, with the latest figure at 222165.62% for Q4 2025.
- For Q4 2025, Net Margin rose 22288734.0% year-over-year to 222165.62%; the TTM value through Dec 2025 reached 256.87%, up 27338.0%, while the annual FY2025 figure was 256.87%, 27338.0% up from the prior year.
- Net Margin for Q4 2025 was 222165.62% at NewAmsterdam Pharma, up from 20691.09% in the prior quarter.
- Across five years, Net Margin topped out at 222165.62% in Q4 2025 and bottomed at 20691.09% in Q3 2025.
- The 3-year median for Net Margin is 1024.51% (2025), against an average of 15752.51%.
- The largest YoY upside for Net Margin was 22288734bps in 2025 against a maximum downside of -2063390bps in 2025.
- A 3-year view of Net Margin shows it stood at 2476.59% in 2023, then plummeted by -129bps to 721.71% in 2024, then soared by 30883bps to 222165.62% in 2025.
- Per Business Quant, the three most recent readings for NAMS's Net Margin are 222165.62% (Q4 2025), 20691.09% (Q3 2025), and 90.7% (Q2 2025).